The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.

Patients with overweight or obesity and heart failure with preserved ejection fraction that have unintentional weight loss have worse outcomes.

The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.

Following priority review, the FDA approved Kerendia for the treatment of patients with heart failure with left ventricular ejection fraction (LVEF) ≥40%.

BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that Henry Ford Health in Detroit, ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

CVRx, Inc. (NASDAQ: CVRX) ('CVRx”), a commercial-stage medical device company, announced today that the Centers for Medicare ...

The era of predictive modeling enhanced with machine learning and artificial intelligence (AI) to aid clinical ...

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.

The US Food and Drug Administration has approved the use of finerenone (Kerendia) in heart failure (HF) patients with mildly ...